Cftr Trikafta denied as experimental or investigational by Humana?

Humana's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Trikafta as "Experimental"

An "experimental or investigational" denial from Humana means the plan has determined — or its automated system has flagged — that the requested use of Trikafta (elexacaftor/tezacaftor/ivacaftor) does not yet meet the plan's standard for established medical practice. For Trikafta used within its FDA-approved indication, this denial is almost always an error: the drug has full FDA approval for cystic fibrosis patients carrying eligible CFTR mutations, and it appears in major cystic fibrosis treatment guidelines published by the Cystic Fibrosis Foundation. The most common trigger is a request for an off-label use (e.g., a mutation or age group that falls outside the current label) — if that applies to your situation, the appeal strategy differs somewhat from an on-label denial.

## Why It Is Appealable

For on-label use, FDA approval is the primary rebuttal to an experimental denial. Federal law under ACA §2719 requires plans to follow an IRO's independent clinical determination, and external reviewers apply objective published clinical evidence — not the plan's internal policy — to evaluate whether a treatment is established or experimental. Trikafta's approval history and inclusion in CF Foundation guidance provides strong support.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the deadline on your EOB. Humana must respond within 30 days (non-urgent) or 72 hours (urgent). Given the seriousness of cystic fibrosis progression, most prescribers can support an expedited request.
• External review (ACA §2719 / ERISA §503): This is one of the strongest denial types for external review, because the IRO applies objective clinical evidence independently. You have approximately 4 months from denial to file. Expedited external review is available when delay poses serious health risk.

## Documentation to Gather

1. FDA approval documentation — print the current FDA-approved prescribing label from FDA.gov; highlight the approved indication and confirm your use falls within it. 2. CFTR genotype report — certified lab report confirming your mutation is within the approved indication. 3. Humana's experimental/investigational policy — request the written policy; confirm whether it explicitly addresses Trikafta and, if so, under what conditions. 4. CF specialist medical-necessity letter — should cite the FDA approval, reference applicable Cystic Fibrosis Foundation treatment guidelines (by organization, not by specific numbers), and explain that this use is the current standard of care for your mutation class. 5. Clinical notes — pulmonary function trajectory, exacerbation history, and overall disease burden to contextualize why timely access matters.

## Criteria-Mapping Structure

| Humana Experimental Basis | Your Counter-Evidence | |---|---| | Claim that use is investigational | FDA approval confirmation (label from FDA.gov, indication section) | | Lack of established clinical consensus | CF specialist letter citing CF Foundation guidelines | | Off-label use (if applicable) | Prescriber letter citing published literature and clinical necessity |

## If the Use Is Off-Label

If your prescriber is requesting Trikafta for a mutation or patient profile not yet explicitly listed in the current label, your appeal must also include published peer-reviewed literature and a detailed medical-necessity argument. Ask your CF specialist to identify the most current published evidence supporting your specific situation and include those citations.